Current biotechnological approaches to the prevention of restenosis.

Current biotechnological approaches to the prevention of restenosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Current biotechnological approaches to the prevention of restenosis. Abstract Text:

S Nikol,A Maier,E Krausz,B ,T Y Huehns,

No systemic pharmacological treatment has been convincingly shown to reduce the incidence of restenosis after angioplasty in patients. The lack of success of many pharmaceutical agents in reducing restenosis rates post-angioplasty and following stent implantation, as documented in dozens of clinical trials, has encouraged the development of new biotechnological approaches to the treatment of restenosis. Gene therapy and other agents, including antibodies, fusion toxins and ribozymes, have the potential to prevent some of the sequelae after arterial injury, particularly cell proliferation. Mechanical methods of preventing restenosis, for example sophisticated local drug delivery strategies and biodegradable stents using new materials, in combination with novel therapeutic agents or radiation, may also be of use.

Current biotechnological approaches to the prevention of restenosis. Publishing Authors By Initials

S Nikol,A Maier,E Krausz,B ,TY Huehns,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Current biotechnological approaches to the prevention of restenosis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: BioDrugs : clinical immunotherapeutics, biopharmac

VOLUME: 9

Page Numbers: 375-88

Journal Abbreviation:

ISSN: 1173-8804

DAY: 20

MONTH: May

YEAR: 1998

Current biotechnological approaches to the prevention of restenosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9705305

Current biotechnological approaches to the prevention of restenosis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Current biotechnological approaches to the prevention of restenosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Current biotechnological approaches to the prevention of restenosis.

AFFILIATION: Medical Department I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BioDrugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Current biotechnological approaches to the prevention of restenosis Related Publications

• Current biotechnological approaches to the prevention of restenosis.
• Ocular changes in patients undergoing long-term desferrioxamine treatment.
• Oxygen dissociation curve in Eales's disease.